Protected environment–Prophylactic antibiotic program for malignant sarcomas: Randomized trial during remission induction chemotherapy
Gerald P. Bodey, Victorio Rodriguez, William K. Murphy et al. · Cancer · 1981
Fifty-one valuable patients with malignant sarcomas were randomly allocated to receive three courses of remission induction chemotherapy with cyclophosphamide, vincristine, Adriamycin, and dimethyl triazeno imidazole carboxamide (CYVADIC) on the protected environment-prophylactic antibiotic for the control group (P = 0.22). The response rates (complete plus partial) were 71% and 67%, respectively. The durations of response were similar for both groups of patients, but the PEPA patients survived substantially longer (median, 84 weeks vs. 58 weeks). The frequency of infection was significantly lower among the PEPA patients, and the doses of CYVADIC could be escalated more often among these patients. Dosage escalation was associated with a higher complete remission rate and lower fatality rate.
Cited by 57 works. doi:10.1002/1097-0142(19810515)47:10<2422::aid-cncr2820471017>3.0.co;2-y Open-access PDF
Authors
References
- A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
- Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia
- Protected Environments and Prophylactic Antibiotics
- Dose response evaluation of adriamycin in human neoplasia
- Infection Prevention in Acute Nonlymphocytic Leukemia
- A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients
- Studies of a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results
- RANDOMIZED TRIAL OF PROTECTED ENVIRONMENT — PROPHYLACTIC ANTIBIOTICS IN 145 ADULTS WITH ACUTE LEUKEMIA
- EFFECT OF PROPHYLACTIC MEASURES ON THE MICROBIAL FLORA OF PATIENTS IN PROTECTED ENVIRONMENT UNITS